Thymulin (Facteur Thymique Serique, FTS-Zn, Serum Thymic Factor)
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
A natural hormone produced by the thymus gland that requires zinc to function and plays an essential role in developing immune cells (T-cells) and building the immune system. It has also shown anti-inflammatory and pain-relieving effects in animal studies, but has never been tested in human clinical trials.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Thymulin is preclinical or hypothesis-only.
This peptide has not been evaluated by the FDA. It is sold as a research chemical and has no regulatory status for human use.
In animal studies, low nanogram doses of thymulin administered locally (intraplantar) or systemically (intraperitoneal) produced hyperalgesia via PGE2-dependent mechanisms PMID 17192563. At higher microgram doses, thymulin and its analogue PAT showed anti-inflammatory and analgesic effects without significant adverse effects PMID 17192563. The 2025 review of thymic peptides noted that an important feature of thymus preparations is their therapeutic safety -- even long-term use does not cause side effects (DOI 10.1007/s10989-024-10666-y). The FDA FAERS database returned no adverse event reports for thymulin. In the topical zinc-thymulin hair loss application, community data reports no adverse systemic effects or local side effects across 3,300 applications (online communities/HairlossResearch). However, formal human safety data for exogenous thymulin injection is entirely lacking because thymulin has never entered clinical trials.
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Every claim on this page links to one of the 10 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.